Company News

Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)

Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX

CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.

Kelun-Biotech will present results of Phase 2 study of SKB264 (TROP2 ADC) in metastatic NSCLC.

KLUS Pharma is attending 2023 ASCO Annual Meeting in Chicago from June 2-6th

KLUS Pharma will attend the BIO International Convention in Boston, MA from June 5-8, 2023.

KLUS Pharma will attend the 2023 AACR Annual Meeting in Orlando, Florida from April 14-19, 2023.

KLUS Pharma will attend 2023 Bio-Europe Spring live and virtual partnering events.

Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

A scientific poster of SKB264 will be presented at 2022 SABCS highlighting key data from Phase 2 TNBC study.

Come meet with us at BIO Partnering at JPM 2023 to learn more about our innovative pipeline!

KLUS Pharma is Attending BioPharm America in Boston from September 28-29